Greg Parker graduated from Imperial College, London with a Masters degree in Chemistry and was subsequently awarded his Ph.D. in Organic Chemistry from The University of Bristol before spending time at The Ohio State University on his post-doc. After a brief foray into the world of pharmaceutical patent analysis, Greg returned to his synthetic roots in the area of process R&D. Greg is a recreational stock market enthusiast, focusing in particular on investments for the long-term including dividend and income investing. Greg also has a strong interest in overseas markets, particularly China, as well as in biotech, commodities, oil/gas, and small cap stocks.
As Managing Editor - Opinion and Analysis, I lead the Seeking Alpha team dedicated to curation of crowdsourced investment research and commentary. My responsibilities are to grow the site's audience, deepen user engagement, and improve editorial processes. I am a CFA charterholder and member of the CFA Society Washington, DC.
I work as a Business System Analyst for a global bio-pharmaceutical company based in Illinois. I am a value-investor that looks for opportunities to exploit market inefficiencies to make out sized profits. I generally am interested in the pharmaceutical industry as well as large income producing companies for value investing. Intense research, intelligence, and patience are the keys to having success with this strategy.
My ultimate objective is to leverage the knowledge, experience and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
My focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
I am a professional investment manager and the founder/CEO of Kuma Star Capital, LLC.
My background is in chemistry and materials engineering. My investing specialization is in growth stocks with an emphasis on short-selling, US technology stocks and Chinese ADRs.
I have been in this game for 12 years. Unfortunately (or fortunately) my first adventures were at the top of the tech bubble where for 5 short months I thought I was invincible. I soon found out how "vincible" I was. After the appropriate mourning period I decided that energy/resource stocks were cheap and became invincible again. Margin in an ever rising market made me, once again, "vincible" . I hope to learn.
My investment interests include small and microcap Biotech stocks with a focus on oncology. I worked for several years as a lab manager and research associate at UCSF Cancer Center in a lab focused on sequencing and assembling tumor genomes, array CGH of intermediate grade prostate tumors, and functional analysis of the oncogenic transcription factor ZNF217. During that time I attended as many talks and lectures as time would allow and read as many papers as possible in the course of investigating possible gene targets in regions of interest from aCGH data.
I have BS in biology and a masters degree in Health services administration.